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What is Already Known about this Subject {#bcp13576-sec-0007}
========================================

Adverse drug reaction (ADR) reporting by patients has been shown to contribute to the detection of new drug safety signals.

What this Study Adds {#bcp13576-sec-0008}
====================

Overall, healthcare professionals (HCPs) reported ADRs that led to drug safety signals slightly earlier than patients.A difference in time to reporting between patients and HCPs was found for signals classified as *important* as well as *nonimportant* medical events.A difference in time to reporting between patients and HCPs was present for reports from the USA, which has a long history of reporting ADRs by patient, but was negligible for reports from Europe, where patients were able to report since 2012, with some countries being earlier.Analysis of the individual signals demonstrated that the difference in median time to reporting between patients and HCPs compared to the total time to signal detection was small for most signals.

Introduction {#bcp13576-sec-0009}
============

Pharmacovigilance centres around the world have an important role to monitor the safety of drugs in the postmarketing phase. They collect information about adverse drug reactions (ADRs) spontaneously reported by healthcare professionals and patients, for example by the Yellow Card Scheme in the UK. Having patients directly reporting to the national pharmacovigilance centres is relatively new in most areas of the world. In 2012 in the European Union, it became mandatory by law for countries to give patients the opportunity to report possible ADRs directly to the competent authority, although several countries introduced reporting by patients earlier [1](#bcp13576-bib-0001){ref-type="ref"}, [2](#bcp13576-bib-0002){ref-type="ref"}. In some countries, such as the USA, patients have already been able to report for decades. Reports from patients are a well‐established source of information in drug safety [3](#bcp13576-bib-0003){ref-type="ref"}. Despite patient participation gaining more and more attention worldwide, this does not necessarily mean that countries have fully embraced patient reporting [4](#bcp13576-bib-0004){ref-type="ref"}, [5](#bcp13576-bib-0005){ref-type="ref"}. More experience and sharing of information between countries is needed to fully understand its value.

Studies already demonstrated that reports by patients positively contribute to pharmacovigilance. Patients generally give an adequate description of the course of clinical symptoms and they seem more likely to report on the impact of ADRs on their daily life compared to healthcare professionals [6](#bcp13576-bib-0006){ref-type="ref"}, [7](#bcp13576-bib-0007){ref-type="ref"}. Some studies found that patients are likely to report more serious ADRs compared to healthcare professionals, while others demonstrate the opposite [8](#bcp13576-bib-0008){ref-type="ref"}, [9](#bcp13576-bib-0009){ref-type="ref"}, [10](#bcp13576-bib-0010){ref-type="ref"}, [11](#bcp13576-bib-0011){ref-type="ref"}, [12](#bcp13576-bib-0012){ref-type="ref"}. There are also studies that demonstrated no difference in seriousness between both groups [6](#bcp13576-bib-0006){ref-type="ref"}, [7](#bcp13576-bib-0007){ref-type="ref"}, [13](#bcp13576-bib-0013){ref-type="ref"}, [14](#bcp13576-bib-0014){ref-type="ref"}. Although there have been concerns about the quality of patient reports in the past, it has recently been shown that the clinical quality of information reported by patients is comparable to that of healthcare professionals [15](#bcp13576-bib-0015){ref-type="ref"}. Concerning the detection of new drug safety signals, it was demonstrated that reports by patient are taken into account [16](#bcp13576-bib-0016){ref-type="ref"}, [17](#bcp13576-bib-0017){ref-type="ref"}, [18](#bcp13576-bib-0018){ref-type="ref"}, [19](#bcp13576-bib-0019){ref-type="ref"}. These signals include ADRs not listed in the Summary of Product Characteristics (SmPC) and new aspects of known ADRs. A recent study in the Netherlands exploring signals detected from 2010 to 2015 showed that the number of reports directly from patients in the signals rose from 16 (10% of total) in 2010 to 161 (28.3% of total) in 2015 [16](#bcp13576-bib-0016){ref-type="ref"}. There were 137 serious reports in all examined signals (30.8% of all patient reports) compared to 224 healthcare professional reports (19.2% of total reports).

Less is known about the difference in timing of reporting by patients and healthcare professionals. It has been suggested that reporting by patients contributes to an earlier detection of drug safety signals [20](#bcp13576-bib-0020){ref-type="ref"}, [21](#bcp13576-bib-0021){ref-type="ref"}. Indeed, a certain number of reports is necessary to generate new drug safety signals and reports by patients provide an additional source of information. In addition, patients may report earlier on certain ADRs compared to healthcare professionals; for the latter group one of the reasons for not reporting a possible ADR to a pharmacovigilance centre may be the uncertainty that it actually concerns an ADR.

Little is known about the extent to which patient reports might impact on timely signal detection and whether this is different for ADRs classified as so called *important medical events* (IMEs), defined as those events that result in death or require (prolonged) hospitalization, and those not classified as IMEs [22](#bcp13576-bib-0022){ref-type="ref"}, [23](#bcp13576-bib-0023){ref-type="ref"}. Furthermore, comparing the USA and Europe may provide additional insights given the extensive experience with patient reporting in the USA, *vs*. Europe where patient reporting is relatively new. In the USA there has been a relatively constant flow of patient reports over time, while in most European countries the number of patient reports continues to rise [3](#bcp13576-bib-0003){ref-type="ref"}, [24](#bcp13576-bib-0024){ref-type="ref"}, [25](#bcp13576-bib-0025){ref-type="ref"}. Also, in the USA patient reports are mostly received through pharmaceutical companies, while in Europe patients mostly report directly to the national pharmacovigilance centre [2](#bcp13576-bib-0002){ref-type="ref"}.

This study aims to explore if there is a difference between patients and healthcare professionals in time to reporting drug--ADR associations that led to drug safety signals. The secondary aims are to explore if there is a difference in time to reporting between patients and healthcare professionals for drug safety signals characterized as IMEs, and if there is a difference for reports from those regions with a long history of patient reporting (USA) *vs*. a region with a short history of patient reporting (Europe).

Method {#bcp13576-sec-0010}
======

Study design and data source {#bcp13576-sec-0011}
----------------------------

This was a retrospective comparison of time to reporting selected drug--ADR associations that led to drug safety signals between patients and healthcare professionals.

ADR reports were selected from the World Health Organization (WHO) global database of individual case safety reports, VigiBase. As of June 2017, this database contained over 15 million ADR reports received from over 120 member countries of the WHO programme for international drug monitoring [26](#bcp13576-bib-0026){ref-type="ref"}.

We selected all reports of drug--ADR associations present in all drug safety signals detected by the Netherlands Pharmacovigilance Centre Lareb between 2011 and 2015. At Lareb, reports by patients were handled in the same way as those from healthcare professionals and they were fully integrated into the process of signal detection. During signal detection, qualitative aspects as well as quantitative aspects (disproportionality analysis) are taken into account [27](#bcp13576-bib-0027){ref-type="ref"}, [28](#bcp13576-bib-0028){ref-type="ref"}. Signals covered a wide range of different ADRs. We excluded signals on drug interactions, multiple suspected drugs, and dosing or administration errors. All signals are publicly accessible on the Lareb website [29](#bcp13576-bib-0029){ref-type="ref"}, [30](#bcp13576-bib-0030){ref-type="ref"}. In total, 60 signals were included in this study.

Based on the drug--ADR associations present in the selected signals, ADR reports were selected from a frozen VigiBase version as of October 2015. Selection of reports in VigiBase was based on the WHO drug classification system, the ATC‐5 code or the drug\'s brand name [31](#bcp13576-bib-0031){ref-type="ref"} and the Medical Dictionary for Regulatory Activities *MedDRA* Preferred term coding [32](#bcp13576-bib-0032){ref-type="ref"}, depending on the drug--ADR association described in the signal. The drug needed to be classified as 'suspected' or 'interacting' on the reports. Reports had to be filed in the database before dissemination of the drug safety signals.

Only reports that had the E2B structure, an international standard for transmitting ADR reports, were included. Only reports that were either pure patient reports (E2B reports with a single reporter whose qualification was *Consumer or other non‐health professional*) or pure healthcare professional reports (E2B reports with a single reporter whose qualification was *Physician*, *Pharmacist* or *Other health professional*) were included. There was no exclusion of duplicate reports; in case the event had been reported by different sources, these were all take into account.

We only included data from countries if they accepted reports from patients at the time of the first report for the specific drug--ADR association in VigiBase. Start date of patient reporting in the specific countries was obtained from literature [2](#bcp13576-bib-0002){ref-type="ref"} or through personal contacts with the national pharmacovigilance centres. This was to ensure that countries not only formally accepted patient reports but actually did so in practice. We excluded data from countries with no patient reports in VigiBase. See Figure [1](#bcp13576-fig-0001){ref-type="fig"} for a flowchart of the Methods of data collection.

![Flowchart of the methods of data collection. Signals\' exclusion criteria concerned: drug interactions, multiple suspected drugs, and dosing or administration errors. ADR, adverse drug reaction; IME, important medical event](BCP-84-1514-g001){#bcp13576-fig-0001}

Outcomes {#bcp13576-sec-0012}
--------

The primary outcome was the difference in time to reporting between patients and healthcare professionals. The secondary outcomes were the differences in time to reporting between patients or healthcare professionals for (i) IMEs *vs*. non‐IMEs, according to the European Medicines Agency (EMA)‐list of Important Medical Events, according to MedDRA terminology [18](#bcp13576-bib-0018){ref-type="ref"}, and (ii) for the USA *vs*. Europe. For Europe, we included countries within the European Union, as well as Iceland and Norway because they participate in EMA regulatory decision making. Although Switzerland does not participate in EMA regulatory decision making, this country accepts reports directly from patients since 2002 and share a similar culture with the rest of Europe. For this reason, we decided to take Switzerland into account as well.

Analysis {#bcp13576-sec-0013}
--------

The date of the first report for each individual signal was used as time zero. All reports on the same drug--ADR association from time zero until signal detection were included. We calculated the difference in time between time zero and the following reports from patients and healthcare professionals for each signal individually. Subsequently, data for all signals were pooled. The percentage of reports originating from patients was calculated and it was determined whether a healthcare professional or a patient made the first report for each signal.

Kaplan--Meier plots were used to visualize the reporting over time by patients and healthcare professionals, respectively. Statistical differences in time to reporting between patients and healthcare professionals were explored on the corresponding survival curves using Mann--Whitney *U* tests. To investigate the secondary outcomes, subanalyses were made for signals classified as (non‐)IMEs and reports from the USA and Europe. In addition, time to reporting was analysed for healthcare professionals in the USA *vs*. Europe, and patients in the USA *vs*. Europe. Statistical significance was based on a *P* value \<0.05. Data were analysed using the statistical software program SPSS Statistics, version 22.0 (SPSS, Chicago, IL, USA).

There may be a large difference between reporting of the first report and the time to signal detection for the individual signals. To explore the meaning of the obtained difference in time to reporting between patients and healthcare professionals, relative differences defined as the difference in median time to reporting by patients and healthcare professionals divided by the total time until signal detection, were analysed. The difference in median between both groups was plotted against the total number of days until signal detection. For calculating the median, all signals with at least three patients and three healthcare professional reports were included.

Results {#bcp13576-sec-0014}
=======

Characteristics of included signals {#bcp13576-sec-0015}
-----------------------------------

In total, 60 signals were included (Table [1](#bcp13576-tbl-0001){ref-type="table-wrap"}). The median time to signal detection, calculated from the date of the first report for each individual signal, was 10.4 years, with an interquartile range of 7.6--13.6 years. The signals included a total number of 2822 reports, of which 1488 (52.7%) were reported by patients and 1334 (47.3%) by healthcare professionals. The proportion of patient reports in the individual signals ranged from 0% to 84.4%, with a median of 25.0%. A total of 13 signals (21.7%) did not contain any reports from patients. For 12 signals (20.0%), the first report was made by a patient, for 48 (80.0%) by a healthcare professional.

###### 

Description of the 60 drug safety signals

  **Drug**                                       **ADR**                                                                 **Total number of reports**   **Number of healthcare professional reports**   **Number of patient reports**    **Mann--Whitney U test, *P* value**   **Ratio** [a](#bcp13576-note-0002){ref-type="fn"}
  ---------------------------------------------- ----------------------------------------------------------------------- ----------------------------- ----------------------------------------------- ------------------------------- ------------------------------------- ---------------------------------------------------
  **Signals with ADRs classified as IMEs**                                                                                                                                                                                                                                   
  **Olanzapine**                                 Cerebrovascular accident                                                185                           83                                              102                                             0.058                                        0.06
  **Ciclosporin**                                Posterior reversible encephalopathy syndrome                            127                           98                                              29                                              0.126                                       --0.08
  **Gabapentin**                                 **Blood glucose decreased and hypoglycaemia**                           76                            **58**                                          18                                              0.026                                        0.39
  **Aripiprazole**                               Hypothyroidism                                                          28                            **14**                                          14                                              0.016                                        0.68
  **Natalizumab**                                Cervical dysplasia                                                      17                            14                                              3                                               0.591                                        n.a.
  **Medroxyprogesterone**                        Injection site necrosis and injection site atrophy                      30                            28                                              2                                               1.00                                         n.a.
  **Proguanil hydrochloride/Atovaquone**         **Psychotic disorder**                                                  11                            9                                               **2**                                           0.036                                        n.a.
  **Aripiprazole**                               Psychosis aggravated                                                    13                            12                                              1                                               0.667                                        n.a.
  **Clindamycin**                                **Acute generalised exanthematous pustulosis**                          8                             7                                               1                                               0.250                                        n.a.
  **Ceftriaxone**                                Hepatitis                                                               15                            14                                              1                                               0.400                                        n.a.
  **Clarithromycin**                             Angioedema                                                              26                            25                                              1                                               0.077                                        n.a.
  **Hydroquinine**                               Hypoglycaemia                                                           2                             1                                               1                                               1.00                                         n.a.
  **Iobitridol**                                 Ventricular fibrillation                                                1                             1                                               0                                               n.a.                                         n.a.
  **Adalimumab**                                 Neuroendocrine carcinoma of the skin                                    5                             5                                               0                                               n.a.                                         n.a.
  **Nitrofurantoin**                             Cutaneous vasculitis                                                    1                             1                                               0                                               n.a.                                         n.a.
  **Tocilizumab**                                Necrotising fasciitis                                                   6                             6                                               0                                               n.a.                                         n.a.
  **Omeprazole**                                 Subacute cutaneous lupus erythematosus                                  4                             4                                               0                                               n.a.                                         n.a.
  **Signals with ADRs classified as non‐IMEs**                                                                                                                                                                                                                               
  ***Fumaric acid***                             ***Progressive multifocal leucoencephalopathy***                        2                             2                                               0                                               n.a.                                         n.a.
  **Lamotrigine**                                Alopecia                                                                453                           88                                              365                                             0.912                                        n.a.
  **Paroxetine**                                 **Migraine**                                                            176                           35                                              **141**                                         0.002                                       --0.10
  **Tamsulosin**                                 Vision blurred, visual acuity reduced and visual impairment             151                           39                                              112                                             0.250                                        0.05
  **Escitalopram**                               **Headache**                                                            235                           128                                             107                                             0.140                                        0.06
  **Fluticasone**                                **Palpitations**                                                        118                           19                                              99                                              0.568                                       --0.01
  **Quetiapine**                                 Paraesthesia                                                            165                           **84**                                          81                                             \<0.001                                       0.20
  **Lamotrigine**                                **Nightmare**                                                           77                            12                                              65                                              0.099                                       --0.16
  **Levonorgestrel**                             Galactorrhoea                                                           75                            23                                              52                                              0.228                                        0.07
  **Quetiapine**                                 Sleep apnoea syndrome                                                   69                            31                                              38                                              0.062                                        0.10
  **Omeprazole**                                 Faeces discoloured                                                      54                            **17**                                          37                                             \<0.001                                       0.35
  **Isotretinoin**                               **Erectile dysfunction**                                                59                            28                                              31                                              0.331                                        0.12
  **Tamsulosin**                                 **Dry mouth**                                                           49                            21                                              28                                              0.437                                       --0.05
  **Rivastigmine**                               **Nightmare and abnormal dreams**                                       33                            13                                              20                                              0.137                                        0.20
  **Tamsulosin**                                 Depression and depressed mood                                           30                            12                                              18                                              0.368                                        0.08
  **Doxycycline**                                Paraesthesia                                                            49                            32                                              17                                              0.179                                       --0,15
  **Sitagliptin**                                Dyspnoea                                                                135                           **121**                                         14                                             \<0.001                                       0,25
  **Dutasteride**                                **Testicular pain**                                                     20                            6                                               14                                              0.659                                       --0,11
  **Metronidazole**                              Oedema peripheral                                                       35                            24                                              11                                              0.958                                        0,00
  **Doxycycline**                                Skin discolouration, skin hyperpigmentation and pigmentation disorder   18                            8                                               10                                              0.122                                        0,09
  **Terbinafine**                                Anosmia, parosmia, hyposmia                                             43                            36                                              7                                               0.392                                       --0,14
  **Trazodone**                                  Urinary incontinence                                                    24                            18                                              6                                               1.00                                        --0,56
  **Isotretinoin**                               Anal fissure                                                            15                            9                                               6                                               0.864                                       --0,12
  **Omeprazole**                                 Erectile dysfunction                                                    14                            9                                               5                                               0.518                                        0,01
  **Azathioprine**                               Chromaturia                                                             12                            8                                               4                                               0.683                                        0,16
  **Metronidazole**                              Tongue discolouration                                                   8                             4                                               4                                               1.00                                         0.06
  **Azathioprine**                               Photosensitivity reaction                                               13                            9                                               4                                               0.825                                        0,04
  **Tramadol**                                   Anorgasmia                                                              6                             2                                               4                                               0.267                                        n.a.
  **Fluconazole**                                Drug eruption                                                           31                            28                                              3                                               0.875                                        0.04
  **Tramadol**                                   Hiccups                                                                 12                            9                                               3                                               0.282                                        0.04
  **Methylphenidate**                            Epistaxis                                                               19                            17                                              2                                               0.140                                        n.a.
  **Pandemrix**                                  Injection site discolouration                                           4                             3                                               1                                               1.00                                         n.a.
  **Duloxetine**                                 Electric shock sensation                                                6                             5                                               1                                               0.667                                        n.a.
  **Lenalidomide**                               Psoriasis                                                               4                             3                                               1                                               1.00                                         n.a.
  **Mirtazapine**                                Urinary retention                                                       27                            26                                              1                                               0.296                                        n.a.
  **Nadroparin**                                 Headache                                                                10                            9                                               1                                               0.200                                        n.a.
  **Terbinafine**                                Hyperacusis                                                             1                             1                                               0                                               n.a.                                         n.a.
  **Desloratadine**                              Increased appetite                                                      3                             3                                               0                                               n.a.                                         n.a.
  **Mercaptopurine**                             Photosensitivity reaction                                               2                             2                                               0                                               n.a.                                         n.a.
  **Buprenorphine**                              Skin depigmentation                                                     2                             2                                               0                                               n.a.                                         n.a.
  **Prednisolone**                               Hiccups                                                                 4                             4                                               0                                               n.a.                                         n.a.
  **Betahistine**                                Hallucination                                                           2                             2                                               0                                               n.a.                                         n.a.
  **Terbinafine**                                Erectile dysfunction                                                    3                             3                                               0                                               n.a.                                         n.a.

Signals are sorted from IME signals to non‐IME signals. And within the IME and non‐IME signals they are sorted from highest to number of patient reports to lowest.

Ratio calculated by: the difference in median days between reports by patients and healthcare professionals divided to the number of days until signal detection

Signals in *italic*: classified as important medical events (IMEs)

Signals in **bold**: first ADR reports was made by a patient.

In case of *P* \< 0.05 the group of reporters that reported earlier is made **bold**.

ADR, adverse drug reaction; n.a., not applicable

A total of 18 (30.0%) signals were classified as IME (Table [1](#bcp13576-tbl-0001){ref-type="table-wrap"}, signals in *italic*) [18](#bcp13576-bib-0018){ref-type="ref"}. Overall, IMEs included fewer reports from patients compared to healthcare professionals, range 0--55.1% (median of 7.2%) *vs*. non‐IMEs 0--84.4% (median of 34.0%). The first report was made by a patient for four IMEs (22.2%) and eight non‐IMEs (19.0%).

Patient reports were from 24 different countries: Belgium, Bulgaria, Canada, the Democratic Republic of the Congo, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Morocco, the Netherlands, Norway, Peru, Portugal, Slovakia, Sweden, Switzerland, Turkey, UK and USA. A total of 2124 reports came from the USA (61.9% patient reports) and 430 from Europe (21.9% patient reports) and 268 from non‐European countries. For reports from the USA, 26.8% of the healthcare professional reports were classified as IMEs and 7.2% of the patient reports. For reports from Europe, 25.4% of the healthcare professional reports were classified as IMEs, and 37.2% of the patient reports.

Comparison in time to reporting {#bcp13576-sec-0016}
-------------------------------

The overall cumulative distribution of time to reporting of patients and healthcare professionals is shown in Figure [2](#bcp13576-fig-0002){ref-type="fig"}. The corresponding Mann--Whitney *U* test suggested that there was a statistically significant difference between these distributions (*P* \< 0.001) Healthcare professionals generally reported earlier than patients with a median time to reporting of 7.0 *vs*. 8.3 years, and corresponding interquartile ranges of respectively 3.9--9.5 and 6.2--10.4 years. For IMEs, healthcare professionals and patients took a median time to reporting of 6.9 *vs*. 8.1 years and for non‐IMEs 7.0 *vs*. 8.2 years (Figure [3](#bcp13576-fig-0003){ref-type="fig"}a, b). In both cases, there was an overall statistically significant difference in the time distribution (*P* \< 0.001). The cumulative distributions of reports from the USA and Europe are shown in Figure [4](#bcp13576-fig-0004){ref-type="fig"}a, b. For the USA, median time to reporting for healthcare professionals and patients was 6.0 *vs*. 8.1 years and for Europe 7.8 *vs*. 7.9 years. The corresponding tests for distribution differences were both significant, *P* \< 0.001 and *P* = 0.03, respectively. In addition, healthcare professionals in the USA reported earlier compared to those in Europe (*P* \< 0.001). For patients, no statistically significant difference was shown (*P* = 0.531).

![The cumulative distribution of time of adverse drug reaction (ADR) reports, after the first ADR report, coming from patients and healthcare professionals, Mann--Whitney *U P* \< 0.001](BCP-84-1514-g002){#bcp13576-fig-0002}

![The cumulative distribution of time of adverse drug reaction (ADR) reports, after the first ADR report, coming from patients and healthcare for: a) important medical events, Mann--Whitney *U P* \< 0.001, b) non‐ important medical events, Mann--Whitney *U P* value of \<0.001](BCP-84-1514-g003){#bcp13576-fig-0003}

![The cumulative distribution of time of adverse drug reaction (ADR) reports, after the first ADR reports, coming from patients and healthcare for: a) study cases coming from the USA, Mann--Whitney *U P* \< 0.001, b) study cases coming from Europe, Mann--Whitney *U P* = 0.03](BCP-84-1514-g004){#bcp13576-fig-0004}

Individual signals {#bcp13576-sec-0017}
------------------

The analysis of the individual signals showed that for seven signals a statistically significant difference in time to reporting between the two groups was present (Table [1](#bcp13576-tbl-0001){ref-type="table-wrap"}). For two of these signals, patients reported significantly earlier than healthcare professionals: 'paroxetine associated with migraine' (*P* = 0.002) and 'proguanil hydrochloride/atovaquone associated with psychotic disorder' (*P* = 0.036).

To explore the meaning of the differences in time to reporting between patients and healthcare professionals, the difference in median days between reports by patients and healthcare professionals divided by the number of days until signal detection, was plotted against the number of days until signal detection (see Figure [5](#bcp13576-fig-0005){ref-type="fig"}). A positive ratio means earlier reporting by healthcare professionals and a negative ratio earlier reporting by patients. The ratio‐lines in the figure give an indication of the meaning of the difference in median between both groups. A small ratio in combination with a high number of days until signal detection indicated little clinical relevance, while a high ratio in combination with a small number of days until signal detection indicated a higher level of clinical relevance. In total, 34 signals were included in the scatter plot; of those, five were classified as IMEs and 29 as non‐IMEs. 19 out of 34 signals had a ratio between --0.1 and 0.1; three of those signals were classified as IMEs and 16 as non‐IMEs. For one signal, there was no difference between patients and healthcare professionals, for 11 signals, patients reported earlier and for 22 healthcare professionals reported earlier. For patients, there was one signal with a ratio of less than --0.3. For healthcare professionals, there were three signals with a ratio over 0.3, including two classified as IMEs.

![Scatterplot of the difference in median days between reports by patients and healthcare professionals divided by the number of days until signal detection, plotted against the number of days until signal detection. Closed bullet = signal classified as non‐IME; open bullet = signal classified as IME, The ratio was calculated by the difference in median divided to the number of days until signal detection. A positive ratio means earlier reporting by healthcare professionals and a negative ratio earlier reporting by patients](BCP-84-1514-g005){#bcp13576-fig-0005}

Discussion {#bcp13576-sec-0018}
==========

With the increasing interest in patients as stakeholders in pharmacovigilance, it is important to explore the impact of patient reporting on early detection of new drug safety signals in pharmacovigilance. We demonstrated that ADRs that led to drug safety signals were generally reported earlier by healthcare professionals than patients, with an overall median difference of 1.3 years. This difference was present for ADRs classified as IMEs as well as non‐IMEs. Although a difference in timing between both groups was present for the USA, the difference was negligible for Europe. The ratios in time to reporting were small, indicating that the difference in time to reporting ADRs between patients and healthcare professionals had limited impact on the overall time to signal detection for most signals.

It has been suggested that patient reports might enable earlier signal detection [20](#bcp13576-bib-0020){ref-type="ref"}, [21](#bcp13576-bib-0021){ref-type="ref"}. In 1996, Egberts *et al*. [21](#bcp13576-bib-0021){ref-type="ref"} compared information obtained from patients and healthcare professionals on the, at the time, new antidepressant paroxetine. At that time in the Netherlands, patients were not yet able to report directly to the pharmacovigilance centre but could consult a telephone medicines information service maintained by pharmacists. Comparing the timing of reports by healthcare professionals to the national pharmacovigilance centre with questions by patients to the telephone service, showed that patients posted questions to this telephone service earlier as compared to healthcare professionals, with a mean time lag for all suspected reactions of 229 days. Hammond *et al*. [33](#bcp13576-bib-0033){ref-type="ref"} explored time to signal detection for four randomly selected GlaxoSmithKline marketed drugs, for reports of patients and healthcare professionals combined and as separate groups. Using disproportionality analysis, 23 signals of disproportionate reporting were identified, of which 52.2% (12 of 23) at an earlier stage when the patient reports were included, 34.8% (eight of 23) in the same year and 13% (three of 23) later when patient reports were included. The aforementioned studies focussed on time‐aspects of statistical drug--ADR reporting associations not necessarily representing safety signals. To our knowledge, including actual drug safety signals to compare time to reporting between patients and healthcare professionals has not been explored before.

To find a new drug safety signal, a certain number of reports is necessary. The introduction of direct patient reporting introduced a growth in the number of reports by patients. This growth also reflects in the amount of patient reports that contributed to new drug safety signals [16](#bcp13576-bib-0016){ref-type="ref"}. In the current study, we found a relatively high proportion of patient reports in the included signals; 52.7% of all reports and a range of 0% to 84.4% for the individual signals. Reports by patients are more represented in ADRs classified as non‐IMEs than IMEs; range of 0--84.4% *vs*. 0--55.1% respectively. Analysing signals individually, we demonstrated that, for some, patients were earlier in reporting and, for others, healthcare professionals were earlier. It is therefore plausible that reports by patients can contribute to earlier signal detection. There are some points to consider concerning the data used for this study. In our study, \>60% of the reports from the USA originated from patients. This was higher than in another analysis from the USA, which showed that from 2006 to 2014 an average of 47% of all reports were from patients [3](#bcp13576-bib-0003){ref-type="ref"}. This may be explained by the nature of the selected signals. It was furthermore striking that the percentage reports classified as IME was higher for patient reports from Europe compared to those coming from the USA. The percentage of IMEs included in all patient reports was in line with previous results of a study on Dutch drug safety signals by van Hunsel *et al*. [16](#bcp13576-bib-0016){ref-type="ref"}. They showed that of all reports by patients that contributed to a signal in the Netherlands from 2010 to 2015, 30.5% included an ADR classified as IME. This was a higher percentage than reports by healthcare professionals (22.5%) [16](#bcp13576-bib-0016){ref-type="ref"}.

By selecting reports from the international database VigiBase, we could include a high number of reports which allowed us to analyse signals by importance of the event and by region of origin. It must be kept in mind that data pooling can influence the outcome. On average, the median time to signal detection, calculated from time zero, was 10.4 years. Given the large variation in number of reports per signal, signals with many reports contributed to a larger extent to the overall outcome. To place our results in perspective, we therefore also explored all signals individually.

The reporting rate may vary over time and may differ between patients and healthcare professionals. It can be influenced by factors, such as media attention or discussions on the internet [34](#bcp13576-bib-0034){ref-type="ref"}, [35](#bcp13576-bib-0035){ref-type="ref"}. As far as we know, there was no specific media attention for the drug--ADR associations included in our study, but differences in timing due to external factors cannot be ruled out. In addition, for Europe due to changes in the pharmacovigilance legislation in 2012 it is possible that this legal change caused a steeper growth in patient reporting compared to healthcare professional reporting. This may have contributed to the difference in time to reporting we found between healthcare professional reports from the USA *vs*. Europe.

Conclusion {#bcp13576-sec-0019}
==========

Patients contributed a large proportion of reports on drug--ADR pairs that eventually became drug safety signals; 53% overall, with a median of 25%. This corroborates earlier findings on the contribution of patient reports to signal detection in pharmacovigilance. For all signals, median time to signal detection was 10.4 years. Healthcare professionals generally reported 1.3 years earlier than patients. This was the case for ADRs classified as IMEs as well as non‐IMEs. This highlights an opportunity to further increase the value of patient reporting in the future, by encouraging patients to report suspected ADRs earlier.
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